GALT, US3632252025

Galectin Therapeutics stock: AASLD presentations spotlight belapectin

Published on 11/05/2026 at 02:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Galectin Therapeutics stock traded at 3.14 euros in late trading on Wednesday. The company is due to present belapectin analyses at AASLD from November 5 to 9.

Galectin advances its liver program

Galectin Therapeutics plans three presentations at the AASLD Liver Meeting in Denver.
The company has submitted a registrational Phase 3 protocol for belapectin to the FDA.
Upcoming clinical and regulatory milestones remain central to the investment case.

GALT, US3632252025, Illustration mit AI erstellt.

Galectin Therapeutics said on October 6 that it will present new belapectin analyses at the American Association for the Study of Liver Diseases Liver Meeting, which runs from Thursday, November 5, through Monday, November 9, in Denver. The company will deliver an oral presentation, a Poster of Distinction presentation and an additional poster presentation based on data from its NAVIGATE and GT-026 Phase 2b trials.

The presentations focus on noninvasive risk assessment for variceal development in patients with MASH cirrhosis and portal hypertension. Galectin also said on October 6 that it had submitted a registrational Phase 3 protocol for belapectin to the U.S. Food and Drug Administration. The company described the submission as a step toward advancing the program in a disease area with no approved treatment options, while clinical and regulatory execution remain key milestones.

Galectin Therapeutics stock traded at 3.14 euros on Lang & Schwarz at 23:00 CET on Wednesday, November 4; the real-time quote of Galectin Therapeutics stock is available here.

The company announced the presentations and protocol submission in a Galectin Therapeutics press release. The oral presentation is scheduled for November 8, while the two poster sessions are scheduled for November 5 and November 7.

Business model and competitive setting

Galectin Therapeutics is a U.S. biotechnology company headquartered in Norcross, Georgia, focused on discovering and developing therapies for chronic liver disease and cancer. Its lead candidate, belapectin, is a galectin-3 inhibitor being developed for MASH cirrhosis with portal hypertension, while additional programs target cancer and other fibrotic diseases. The company is in the clinical-development stage, making trial results, regulatory decisions and financing important drivers of its outlook.